Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 11/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | MPI | P34949 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | PRKCI | P41743 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554267 | 0.86 | PRKCZ (0.69) | PRKCZALDH1A1MAPTGAAKEAP1 | |
| SCHEMBL689476 | 0.84 | PRKCZ (0.67) | PRKCZALDH1A1MAPTGAAKEAP1 | |
| SCHEMBL688430 | 0.83 | PRKCZ (0.63) | PRKCZALDH1A1MAPTGAAKEAP1 | |
| SCHEMBL1190649 | 0.82 | PRKCZ (0.80) | PRKCZALDH1A1MAPTGAAKEAP1 | |
| SCHEMBL18342647 | 0.82 | ALDH1A1 (0.60) | PRKCZALDH1A1MAPTGAAKEAP1 | |
| SCHEMBL13837698 | 0.82 | PRKCZ (1.00) | PRKCZALDH1A1MAPTGAAKEAP1 | |
| SCHEMBL689204 | 0.80 | PRKCZ (1.00) | PRKCZALDH1A1MAPTGAAKEAP1 | |
| SCHEMBL689452 | 0.80 | PRKCZ (0.80) | PRKCZALDH1A1MAPTGAAKEAP1 | |
| SCHEMBL8290826 | 0.80 | PRKCZ (0.79) | PRKCZALDH1A1MAPTGAAKEAP1 | |
| SCHEMBL1553418 | 0.80 | PRKCZ (0.64) | PRKCZALDH1A1MAPTGAAKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744812-B1 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-07-20 | — | — | EP | disclosed |
| US-9227984-B2 | Therapeutically active fused pyrimidine derivatives | UCB PHARMA S.A. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-10-16 | — | — | US | disclosed |
| EP-2744812-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013024291-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012100732-A1 | RETINOID-RELATED ORPHAN RECEPTOR GAMMA MODULATORS, COMPOSITION CONTAINING THEM AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2012-08-02 | — | — | WO | disclosed |
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1953148-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20060183759-A1 | Tissue transglutaminase inhibitors | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2006-08-17 | — | — | US | disclosed |
| WO-2006060702-A1 | SUBSTITUED 3,4-DIHYDROTHIENO [2,3-D] PYRMIDINES AS TISSUE TRANSGLUTAMINASE INHIBITORS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2005033102-A2 | THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | HAVCR2, TPMT, PAICS | PRKCZ 2221/4885ALDH1A1 1119/4885MAPT 3001/4885 |
| US-20060183759-A1 | Tissue transglutaminase inhibitors | TGM2, HNMT, TPMT | PRKCZ 3494/4885ALDH1A1 3116/4885MAPT 40/4885 |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | MMP2, MMP9, MMP1 | PRKCZ 4810/4885ALDH1A1 423/4885MAPT 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.